TIMELINE-Gene therapy’s long road to market – Reuters
|
TIMELINE-Gene therapy’s long road to market
Reuters LONDON, Aug 8 (Reuters) – Gene therapy, which aims to patch faulty genes with working DNA, has been a long time in development. The following are major milestones: 1972 – Researchers first suggest gene therapy as a treatment for genetic diseases but … |
|
Timeline: Gene therapy’s long road to market
Reuters LONDON (Reuters) – Gene therapy, which aims to patch faulty genes with working DNA, has been a long time in development. The following are major milestones: 1972 – Researchers first suggest gene therapy as a treatment for genetic diseases but oppose … |
eNCA |
Drugmakers’ hopes for gene therapy rise despite tiny sales in Europe
eNCA After decades of frustrations, firms believe there are now major opportunities for gene therapy in treating inherited conditions such as haemophilia. They argue that therapies offering one-off cures for intractable diseases will save health providers … |
pharmaphorum |
Kite begins EU trial of CAR–T therapy
pharmaphorum Axicabtagene ciloleucel is an investigational therapy in which a patient’s T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19 – a protein expressed on the cell surface of B-cell lymphomas and leukaemias – and … Kite Submits Investigational New Drug (IND) Application for KITE-585, Anti-BCMA CAR–T Therapy Candidate for …Business Wire (press release) Prepping for a rapid-fire launch, Kite Pharma gets a pass from FDA on axi-cel panel reviewEndpoints News Kite Pharma (KITE) Q2 Loss Narrower than Expected, Sales BeatNasdaq Modern Readers –Zacks Investment Research all 52 news articles » |